Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B

Abstract

Hepatitis B virus (HBV) infection continues to be a worldwide public health problem. In Mexico, at least three million adults are estimated to have acquired hepatitis B (total hepatitis B core antibody [anti-HBc]-positive), and of those, 300,000 active carriers (hepatitis B surface antigen [HBsAg]-positive) could require treatment. Because HBV is preventable through vaccination, its universal application should be emphasized. HBV infection is a major risk factor for developing hepatocellular carcinoma. Semi-annual liver ultrasound and serum alpha-fetoprotein testing favor early detection of that cancer and should be carried out in all patients with chronic HBV infection, regardless of the presence of advanced fibrosis or cirrhosis. Currently, nucleoside/nucleotide analogues that have a high barrier to resistance are the first-line therapies.

Keywords: Acute hepatitis; Antígeno de superficie de la hepatitis B; Chronic hepatitis; Elastografía de transición; Entecavir; Hepatitis B surface antigen; Hepatitis B virus; Hepatitis aguda; Hepatitis crónica; Métodos no invasivos para evaluar la fibrosis; Noninvasive methods for evaluating fibrosis; Tenofovir alafenamida; Tenofovir alafenamide; Tenofovir disoproxil fumarate; Tenofovir disoproxil fumarato; Transition elastography; Virus de la hepatitis B.